An interventional study of Guidance of the treating physician by a digital tool in Chronic Obstr Lung Disease, sponsored by Prima Vard AB. Completed at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Prima Vard AB · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden — 16 open to participants now, 24 under way, 6 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sweden.
Among the 152 studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden, this one is the 117th largest by enrollment of the 123 interventional ones that give a count, is one of 4 that started in 2026, is one of 35 with no phase, and was the 152nd registered.
5,526 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →16 of the 152 studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden are open now. Recruiting first, the newest first:
Grifols Therapeutics LLC · Sites in Sweden, United States, Denmark and 6 more countries
Ages 18–80
Björn Nordlund · Sites in Sweden
Ages 40+
Sanofi · Sites in Sweden, United States, Argentina and 19 more countries
Ages 40–85
Sanofi · Sites in Sweden, United States, Argentina and 22 more countries
Ages 40–80
GlaxoSmithKline · Sites in Sweden, United States, Argentina and 20 more countries
Ages 40–80
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 24 · Phase 3 44 · Phase 4 15
First in 1987; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 62 across 3,844 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 229 across the 123 interventional studies, 470 across the 28 observational. Of the 124 that completed or were terminated, 55 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
100 of 152 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Prima Vard AB as lead sponsor.
Prima Vard AB has 1 study filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
6 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT01460264Region SkaneAn Open Prospective Longitudinal Pulmonary-cardiovascular Cohort Study | 2026-12 |
| NCT05008081Wim JanssensThe CATALINA Study | 2027-03 |
| NCT07573098Björn NordlundDigital Tool for Improved Self-management of COPD | 2027-05-05 |
Add all 6 to your calendar (.ics) → With an account.
Among the 152 studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The inadequate fulfillment of national targets for COPD described above indicates that interventions designed to increase adherence to recommendations in established guidelines could improve patient outcomes. This pilot study is therefore intended to indicate if a digital educational tool can increase adherence to COPD guidelines and measurably improve measures of disease control. If the objectives of the study are met, it provides a rationale for further developing the tool and validating it in controlled studies. This is an 8-week, single-arm pilot study in patients with COPD. A total of 35 patients will be included. Based on an anticipated screening failure rate of 50%, 70 patients will be screened. Patients will receive standard of care with a board-certified physician using an educational COPD tool.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention guided by the digital tool
Other: Guidance of the treating physician by a digital tool
The intervention is that the treating physician will be guided by a digital tool describing treatment recommendations for COPD. The choice of treatment will be made by the investigator, based on his or her clinical judgment supplemented with support from the educational tool. All participating patients in the study will be treated by a physician that uses the tool.
CAT score
Change in COPD assessment test (CAT) score
Time frame: 8 weeks
mMRC
Change in mMRC (modified medical research council) score
Time frame: 8 weeks
Walking distance
Change in walking distance on a 6 minute walk test
Time frame: 8 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Mar 2026 to primary completion in Oct 2026, 6 months.
Of 1,097 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 6 months is below that.
Counting every sponsor, half of 1,185 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →